Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for EVO756 (MRGPRX2 Antagonist) in Moderate-To-Severe Atopic Dermatitis. The expected timing is based on the latest available company guidance and may change.
03/05/26:- Ph2b AD dose-ranging trial enrolling; topline data expected H2 2026. 05/07/26:- Ph2b AD trial enrollment complete; topline data on track for Q3 2026. 08/06/26:- Ph2b AD top-line data expected in September 2026.
Verification
Confirm timing and program details against the company announcement or filing.